Loading
A phase 3 trial in colorectal cancer, run by Charite University, Berlin, Germany, not yet recruiting.
Continuous or Intermittent Cetuximab Plus FOLFIRI as First-line Treatment in RAS/BRAF Wild-type mCRC Patients is a phase 3, randomised interventional study registered as NCT07004413 by Charite University, Berlin, Germany, with a registry enrolment figure of 267 participants, started 2026-10-01 and due to reach its primary completion in 2028-10-01. Interventions recorded: FOLFIRI+cetuximab; Guardant360 ctDNA assay. Conditions listed: Colorectal Cancer Metastatic. Primary outcome: Progression-free survival (PFS) on treatment rate at 12 months. Colorectal eligibility wording from the registry: "Histologically confirmed, UICC stage IV unresectable adenocarcinoma of the colon or rectum". Sites: Germany. No results are recorded here; the registry entry is the source.
Shares MRD / molecular residual disease testing, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares MRD / molecular residual disease testing, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares MRD / molecular residual disease testing, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares MRD / molecular residual disease testing, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares MRD / molecular residual disease testing, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares MRD / molecular residual disease testing, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares MRD / molecular residual disease testing, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares MRD / molecular residual disease testing, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.